Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
Unicycive Therapeutics (Nasdaq: UNCY), a clinical-stage biotech company focused on kidney disease treatments, has announced its participation in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference. The company's CEO, Dr. Shalabh Gupta, will engage in a fireside chat on July 14, 2025, at 11:00 AM ET.
Investors and interested parties can access the webcast through the Events and Presentations section of Unicycive's website under the Investors tab.
Unicycive Therapeutics (Nasdaq: UNCY), una società biotecnologica in fase clinica specializzata in trattamenti per le malattie renali, ha annunciato la sua partecipazione al prossimo H.C. Wainwright 4th Annual Kidney Virtual Conference. Il CEO dell'azienda, Dr. Shalabh Gupta, parteciperà a una conversazione informale il 14 luglio 2025 alle 11:00 ET.
Investitori e soggetti interessati potranno seguire la diretta web tramite la sezione Eventi e Presentazioni del sito di Unicycive, nella scheda Investitori.
Unicycive Therapeutics (Nasdaq: UNCY), una empresa biotecnológica en etapa clínica centrada en tratamientos para enfermedades renales, ha anunciado su participación en la próxima Conferencia Virtual Anual de Riñón H.C. Wainwright 4. El CEO de la compañía, Dr. Shalabh Gupta, participará en una charla informal el 14 de julio de 2025 a las 11:00 AM ET.
Los inversores y partes interesadas podrán acceder a la transmisión en vivo a través de la sección de Eventos y Presentaciones en la pestaña de Inversores del sitio web de Unicycive.
Unicycive Therapeutics (나스닥: UNCY)는 신장 질환 치료에 중점을 둔 임상 단계의 바이오텍 회사로, 다가오는 H.C. Wainwright 제4회 연례 신장 가상 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 CEO인 Dr. Shalabh Gupta가 2025년 7월 14일 오전 11시(동부 시간)에 비공식 대화에 참여할 예정입니다.
투자자 및 관심 있는 분들은 Unicycive 웹사이트의 투자자 탭 내 이벤트 및 발표 섹션을 통해 웹캐스트에 접속할 수 있습니다.
Unicycive Therapeutics (Nasdaq : UNCY), une société biotechnologique en phase clinique spécialisée dans les traitements des maladies rénales, a annoncé sa participation à la prochaine conférence virtuelle annuelle H.C. Wainwright sur les reins. Le PDG de la société, Dr Shalabh Gupta, participera à une discussion informelle le 14 juillet 2025 à 11h00 ET.
Les investisseurs et les parties intéressées pourront accéder à la diffusion en direct via la section Événements et Présentations de la page Investisseurs du site web d'Unicycive.
Unicycive Therapeutics (Nasdaq: UNCY), ein biotechnologisches Unternehmen in der klinischen Phase mit Schwerpunkt auf Nierenerkrankungen, hat seine Teilnahme an der bevorstehenden H.C. Wainwright 4th Annual Kidney Virtual Conference angekündigt. Der CEO des Unternehmens, Dr. Shalabh Gupta, wird am 14. Juli 2025 um 11:00 Uhr ET an einem Gespräch im kleinen Kreis teilnehmen.
Investoren und Interessierte können den Webcast über den Bereich Veranstaltungen und Präsentationen auf der Investorenseite der Unicycive-Website verfolgen.
- None.
- None.
LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025 at 11 a.m. ET.
A link to the webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
Investor Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Rachel Visi
Real Chemistry
redery@realchemistry.com
SOURCE: Unicycive Therapeutics, Inc.
FAQ
When is Unicycive Therapeutics (UNCY) presenting at the H.C. Wainwright Kidney Conference?
How can investors access Unicycive's (UNCY) presentation at the H.C. Wainwright conference?
Who will be presenting for Unicycive (UNCY) at the H.C. Wainwright Kidney Conference?
What type of company is Unicycive Therapeutics (UNCY)?
